BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16394991)

  • 21. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.
    Gaines KK
    Urol Nurs; 2004 Feb; 24(1):46-8. PubMed ID: 15054911
    [No Abstract]   [Full Text] [Related]  

  • 24. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
    Harv Health Lett; 2004 Jan; 29(3):3. PubMed ID: 14734283
    [No Abstract]   [Full Text] [Related]  

  • 27. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
    Prisant LM
    Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].
    Jin W; Huang YR
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):708-12. PubMed ID: 16209216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
    Kloner RA
    Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education.
    Hackett GI
    Clin Cornerstone; 2005; 7(1):57-65. PubMed ID: 16156424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
    Ozgur BC; Gonenc F; Yazicioglu AH
    Urol J; 2009; 6(4):267-71. PubMed ID: 20027555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
    Chung E
    J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
    [No Abstract]   [Full Text] [Related]  

  • 36. [PDE5 inhibitors in treatment of benign prostatic syndrome].
    Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
    Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
    Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
    Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
    Nandipati KC; Raina R; Agarwal A; Zippe CD
    Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.